Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium animalis lactis has been investigated for its potential to reduce side effects associated with chemotherapy, particularly gastrointestinal toxicity such as diarrhea and mucositis. Several clinical trials and animal studies suggest that certain probiotic strains, including B. animalis lactis, may help maintain or restore the integrity of the gut microbiota, reduce inflammation, and support mucosal barrier function during chemotherapy. For example, some randomized controlled trials have indicated that probiotic supplementation can lower the incidence and severity of chemotherapy-induced diarrhea in cancer patients, although these studies often use multi-strain formulations (including B. animalis lactis) rather than this strain alone.

The proposed mechanisms include modulation of immune responses, enhancement of epithelial barrier function, and production of beneficial metabolites such as short-chain fatty acids. However, while these findings are promising, the evidence specifically for B. animalis lactis as a single agent remains limited and somewhat preliminary. Most guidelines and systematic reviews acknowledge that probiotics may have a role in supportive care for chemotherapy-induced gastrointestinal symptoms, but they also emphasize the need for more well-designed, strain-specific clinical trials.

Given the current literature, the use of B. animalis lactis for reducing chemotherapy side effects is supported by some scientific evidence, but this evidence is not robust or definitive (hence the rating of 2/5). Safety considerations are also important, especially in immunocompromised patients, so use should be guided by a healthcare professional.

More about Bifidobacterium animalis lactis
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Bifidobacterium animalis lactis

Products containing Bifidobacterium animalis lactis